LENTECHS

LENTECHS, LLC is a privately-held, clinical stage ophthalmic medical device company that aims to revolutionize the contact lens industry with its new generation of soft, suspended contact lens. APIOC™, the flagship contact lens platform, features a patented design for suspension of the lens from behind the upper eyelid, based on the anatomy of the eye. Founded in 2017 by optometrist inventors Melissa Bailey, OD, PhD and Joe Barr, OD, MS, FAAO, LENTECHS has successfully developed its core technology licensed from The Ohio State University. The company is set to launch APIOC for Presbyopia and APIOC for Presbyopia with Astigmatism in early-2022, offering presbyopic individuals the possibility of achieving glasses-like vision with the freedom of a soft contact lens. LENTECHS, headquartered in Columbus, Ohio, has garnered significant support from a network of investors committed to pushing the boundaries of innovation in contact lenses. The most recent $6.00M Venture Round investment on 24 October 2023 involved notable backers including Rev1 Ventures, Ohio Innovation Fund, Bluestem Capital, and the JobsOhio Growth Capital Fund. With its groundbreaking technology and strong financial backing, LENTECHS is poised to make a significant impact in the fields of biotechnology and healthcare.